O pening of the voltage-dependent Ca 2ϩ channels permits influx of Ca 2ϩ across the plasma membrane, triggering diverse physiological processes. These channels are widely distributed in the cardiovascular system, constituting the main route for Ca 2ϩ entry essential for excitation and contraction. Ten unique ␣1 subunits, grouped in 3 families (CaV1, CaV2, and CaV3), that encode the low-voltageactivated T-type and the high-voltage-activated L-, N-, P/Q-and R-type Ca 2ϩ channels, have been identified. 1,2 L-type Ca 2ϩ channels are predominantly expressed in the hearts and peripheral vasculature and serve as the preferred molecular target of the initial Ca 2ϩ channel antagonists in the treatment of hypertension. 3 Recently, a growing body of evidence has accumulated depicting important roles of T-type Ca 2ϩ channels in the regulation of cardiovascular function, such as generation of pacemaker potential and regulation of arterial resistance. 3, 4 T-type Ca 2ϩ channels are found in various cell types, including neurons, cardiomyocytes, vascular smooth muscle cells, and endocrine cells, where they participate in a variety of physiological processes, such as low-threshold Ca 2ϩ spike generation, action potential firing, pacemaking, impulse conduction, maintenance of myogenic tone, cell proliferation, and hormone secretion. 1 In addition to their predominant role in the regulation of vascular function, T-type Ca 2ϩ channels are also involved in cardiomyocyte growth and survival. 3 T-type Ca 2ϩ channel blockers are capable of interrupting certain pathological hypertrophic signaling pathways, including calcineurin-mediated nuclear factor of activated T cells-3 activation. 1 The importance of voltage-dependent Ca 2ϩ channels is demonstrated by the clinical efficacy of Ca 2ϩ channels blockers in certain disease conditions, as well as the widespread distribution and function of these channels. 1 Three classes of chemically distinct L-type Ca 2ϩ channel blockers have been widely used clinically depending on their biophysical and conformation-dependent interactions with the L-type Ca 2ϩ channel. These 3 classes include the dihydropyridine, the phenylalkylamine (verapamil), and the benzothiazepine (diltiazem). Dihydropyridines are characterized by greater potency as vasodilators with less cardiodepressant properties than the other 2 types of Ca 2ϩ channel blockers.
Although the clinical benefits of L-type Ca 2ϩ channel blockers have been well defined, the clinical value of T-type Ca 2ϩ channel blockade remains somewhat elusive. The newly developed dihydropyridine Ca 2ϩ channel blockers, including manidipine, nilvadipine, benidipine, and efonidipine, as well as the benzimidazole mibefradil, appear to possess vasodilatory properties other than blockade of L-type Ca 2ϩ channels. 1, 4 These Ca 2ϩ channel blockers may antagonize both L-and T-type Ca 2ϩ channels, which possibly underlie their excellent clinical profiles, such as minimum reflex tachycardia and renal protection. Nonetheless, controversy still exists with regard to the precise role of T-type Ca 2ϩ channels in the regulation of vascular tone. Mice deficient in CaV3.2 T-type Ca 2ϩ channels display normal contractile responses and reduced acetylcholine-induced relaxation. 2 Moreover, mibefradil exerts little effect on blood pressure or peripheral resistance in mice with conditional knockout of L-type Ca 2ϩ channels. 2 R(-)-enantiomer of efonidipine, with a greater selectivity for T-type Ca 2ϩ channels over efonidipine, fails to alter blood pressure in hypertensive rats. The presence of T-but not L-type Ca 2ϩ channel mRNA, was confirmed in microvessels with a diameter Ͻ40 m. 5 T-type Ca 2ϩ channels are highly expressed in the microvasculature, including mesenteric and cremaster arterioles. Inhibition of these channels by mibefradil dampens vasoconstriction of these arterioles, although such effect seems to be attributed to L-type Ca 2ϩ channel blockade. 2 In this issue of Hypertension, Ball et al 6 compared the inhibition of vascular contractile responses by L-type Ca 2ϩ channel blockers (verapamil and nifedipine) and combined L-/T-type Ca 2ϩ channel blockers (mibefradil and efonidipine) in large conduit (rat aorta) and small (rat mesenteric and human subcutaneous) vessels. Although all 4 of the Ca 2ϩ channel blockers inhibited contractile responses to a similar extent in large vessels, the combined L-/T-type Ca 2ϩ channel blockers produced a significantly greater inhibition of contraction than L-type Ca 2ϩ channel blockers alone in small vessels. Such a differential T-channel effect in microvessels was supported by a greater expression of T-type as opposed to L-type Ca 2ϩ channels in microvessels but not large vessels. Given that microvessels play a pivotal role in the regulation of blood pressure, renal perfusion, and coronary blood flow, their findings implicate that T-type Ca 2ϩ channels may contribute to the additional benefits of the combined L-/Ttype Ca 2ϩ blockers in treating renal and cardiovascular
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From 2 Inhibition of L-type Ca 2ϩ channel causes dilation of afferent but not efferent arterioles, which potentially results in glomerular hypertension. This observation also indicates an intrarenal heterogeneity in the distribution of L-type Ca 2ϩ channels. To the contrary, combined L-/T-type Ca 2ϩ channel blockers, eg, mibefradil and efonidipine, dilate afferent and efferent arterioles, suggesting the presence of T-type Ca 2ϩ channels in both arterioles, as well as a potential impact on intraglomerular pressure and renoprotection of combined L-/T-type Ca 2ϩ blockers. 2 However, other factors, such as the microheterogeneity of vascular beds and other types of Ca 2ϩ influx, cannot be excluded. 3 In addition, data from Ball et al 6 provide further support for an important role for the T-type Ca 2ϩ channel in the regulation of contractile responses in the microvasculature. Although the precise role of T-type Ca 2ϩ channels in vascular beds remains to be determined, they may be associated with gene-activated cell replication and growth during pathological changes in the vasculature. 3 Combined L-/T-type Ca 2ϩ channel blockers may possess greater efficacy than classical L-type Ca 2ϩ channel blockers in the management of blood pressure and renal function. In a recent clinical investigation, Ͼ80% of patients displayed a significant reduction of blood pressure or achieved optimal blood pressure after a switch from amlodipine to benidipine. Moreover, the changeover improved urinary protein excretion and glomerular filtration rate, which correlated with reduced urinary protein. 7 These observations are consistent with better antihypertensive and renoprotective effects of the combined L-/T-Ca 2ϩ channel blockers. In addition, combined L-/T-type Ca 2ϩ channel blockers possess a superior endothelial effect. The endothelial function index, a ratio of flow-mediated dilatation:nitroglycerin-mediated dilatation, was significantly increased in patients with essential hypertension after treatment of efonidipine but not nifedipine. Meanwhile, urinary excretion 8-hydroxy-2Ј-deoxyguanosine and serum malondialdehyde-modified low-density lipoprotein were decreased by efonidipine but not nifedipine, indicating a likely role of oxidative stress reduction in the efonidipine-induced improvement of vascular endothelial dysfunction. 8 A schematic diagram is provided illustrating the benefit of combined L-/T-type Ca 2ϩ channel blockers (Figure) .
One common adverse effect of the L-type Ca 2ϩ channel blockers is vasodilatory edema. Combined L-/T-type Ca 2ϩ channel blockers, such as mibefradil, display antihypertensive efficacy similar to their predecessors with much less propensity of edema formation. It is believed that combined L-/T-type Ca 2ϩ channel blockers equalize the hydrostatic pressure across the capillary bed through equal arteriolar and venular dilatation, thus reducing vasodilatory edema. 9 Taken together, the incremental microcirculatory benefits of the combined L-/T-type Ca 2ϩ channel blockers over the conventional L-type Ca 2ϩ channel blockers are likely attributed to their additional T-type Ca 2ϩ channel blocking properties and the increased presence of T-type Ca 2ϩ channels in the microvasculature. However, adverse events associated with Ca 2ϩ channel blockers, especially the high-profile withdrawal of mibefradil from the market because of unfavorable drug-drug interaction, have led to a heated controversy over the safety, efficacy, and overall clinical merit of combined L-/T-type Ca 2ϩ channel blockers. In general, these Ca 2ϩ channel blockers, like other dihydropyridine Ca 2ϩ channel blockers, demonstrate a more desirable profile when used as part of combination therapy. 10 Additional study is warranted to quantify T-and L-type Ca 2ϩ channels in the human vasculature and to assess the risk:benefit ratio of L-/T-type Ca 2ϩ channel blockers. These efforts should foster novel approaches to discover potent and selective T-type Ca 2ϩ channel modulators not only as potential drugs in the therapeutic armamentarium against cardiovascular disease but also as tools for a better understanding of the physiological roles of T-type Ca 2ϩ channels.
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Figure.
Schematic diagram illustrating vascular regulatory effects of L-type and combined L-/T-type Ca 2ϩ channel blockers in large and microvessels. The L-type Ca 2ϩ channels (LCC) are predominantly expressed in large vessels, whereas T-type Ca 2ϩ channels (TCC) prevail mainly in microvessels. The tissue heterogeneity of TCC and less undesirable effects may offer additional benefit for the combined L-/T-type Ca 2ϩ channel blockers. The "T" end arrows denote inhibition.
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